GlaxoSmithKline expands its cancer scope with $1.9B Sierra Oncology acquisition
GlaxoSmithKline is further building out its cancer drug portfolio by acquiring Sierra Oncology, a biotech whose FDA-ready myelofibrosis drug has clinical data showing advantages over […]